Yu-Sen Huang1,2,3, Jenny Ling-Yu Chen1,4,5, Feng-Ming Hsu4, Jei-Yie Huang6, Wei-Chun Ko2, Yi-Chang Chen2, Fu-Shan Jaw1, Ruoh-Fang Yen6, Yeun-Chung Chang2. 1. Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, Taipei, Taiwan. 2. Department of Medical Imaging, National Taiwan University, Hospital and National Taiwan, University College of Medicine, Taipei, Taiwan. 3. Department of Medical Imaging, National Taiwan University Hospital, Yun-Lin Branch, Yun-Lin, Taiwan. 4. Department of Oncology, National Taiwan University, Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. 5. Department of Radiation Oncology, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu, Taiwan. 6. Department of Nuclear Medicine, National Taiwan University, Hospital and National Taiwan, University College of Medicine, Taipei, Taiwan.
Abstract
PURPOSE: To evaluate the response in patients undergoing SBRT using dynamic contrast-enhanced (DCE) integrated magnetic resonance positron emission tomography (MR-PET). Stereotactic body radiation therapy (SBRT) is efficacious as a front-line local treatment for non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We prospectively enrolled 19 lung tumors in 17 nonmetastatic NSCLC patients who were receiving SBRT as a primary treatment. They underwent DCE-integrated 3T MR-PET before and 6 weeks after SBRT. The following image parameters were analyzed: tumor size, standardized uptake value (SUV), apparent diffusion coefficient, Ktrans , kep , ve , vp , and iAUC60 . Chest computed tomography (CT) was performed at 3 months after SBRT. RESULTS: SBRT treatment led to tumor changes including significant decreases in the SUVmax (-61%, P < 0.001), Ktrans mean (-72%, P = 0.005), Ktrans standard deviation (SD; -85%, P = 0.046), kep mean (-53%, P = 0.014), kep SD (-63%, P = 0.001), and vp SD (-58%, P = 0.002). The PET SUVmax was correlated with the MR kep mean (P = 0.002) and kep SD (P < 0.001). The percentage reduction in Ktrans mean (P < 0.001) and kep mean (P = 0.034) at 6 weeks post-SBRT were significantly correlated with the percentage reduction in tumor size, as measured using CT at 3 months after SBRT. Univariate analyses revealed a trend toward disease progression when the initial SUVmax > 10 (P = 0.083). CONCLUSION: In patients with NSCLC who are receiving SBRT, DCE-integrated MR-PET can be used to evaluate the response after SBRT and to predict the local treatment outcome. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2018;47:191-199.
PURPOSE: To evaluate the response in patients undergoing SBRT using dynamic contrast-enhanced (DCE) integrated magnetic resonance positron emission tomography (MR-PET). Stereotactic body radiation therapy (SBRT) is efficacious as a front-line local treatment for non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We prospectively enrolled 19 lung tumors in 17 nonmetastatic NSCLCpatients who were receiving SBRT as a primary treatment. They underwent DCE-integrated 3T MR-PET before and 6 weeks after SBRT. The following image parameters were analyzed: tumor size, standardized uptake value (SUV), apparent diffusion coefficient, Ktrans , kep , ve , vp , and iAUC60 . Chest computed tomography (CT) was performed at 3 months after SBRT. RESULTS:SBRT treatment led to tumor changes including significant decreases in the SUVmax (-61%, P < 0.001), Ktrans mean (-72%, P = 0.005), Ktrans standard deviation (SD; -85%, P = 0.046), kep mean (-53%, P = 0.014), kep SD (-63%, P = 0.001), and vp SD (-58%, P = 0.002). The PET SUVmax was correlated with the MR kep mean (P = 0.002) and kep SD (P < 0.001). The percentage reduction in Ktrans mean (P < 0.001) and kep mean (P = 0.034) at 6 weeks post-SBRT were significantly correlated with the percentage reduction in tumor size, as measured using CT at 3 months after SBRT. Univariate analyses revealed a trend toward disease progression when the initial SUVmax > 10 (P = 0.083). CONCLUSION: In patients with NSCLC who are receiving SBRT, DCE-integrated MR-PET can be used to evaluate the response after SBRT and to predict the local treatment outcome. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2018;47:191-199.
Authors: Hayley M Reynolds; Bimal K Parameswaran; Mary E Finnegan; Diana Roettger; Eddie Lau; Tomas Kron; Mark Shaw; Sarat Chander; Shankar Siva Journal: PLoS One Date: 2018-08-16 Impact factor: 3.240
Authors: Matthew Mouawad; Heather Biernaski; Muriel Brackstone; Michael Lock; Brian Yaremko; Olga Shmuilovich; Anat Kornecki; Ilanit Ben Nachum; Giulio Muscedere; Kalan Lynn; Frank S Prato; R Terry Thompson; Stewart Gaede; Neil Gelman Journal: Clin Transl Radiat Oncol Date: 2019-12-25
Authors: Dora Correia; Barbara Moullet; Jennifer Cullmann; Rafael Heiss; Ekin Ermiş; Daniel M Aebersold; Hossein Hemmatazad Journal: Radiat Oncol Date: 2022-02-21 Impact factor: 3.481
Authors: Florent L Besson; Brice Fernandez; Sylvain Faure; Olaf Mercier; Andrei Seferian; Xavier Mignard; Sacha Mussot; Cecile le Pechoux; Caroline Caramella; Angela Botticella; Antonin Levy; Florence Parent; Sophie Bulifon; David Montani; Delphine Mitilian; Elie Fadel; David Planchard; Benjamin Besse; Maria-Rosa Ghigna-Bellinzoni; Claude Comtat; Vincent Lebon; Emmanuel Durand Journal: EJNMMI Res Date: 2020-07-30 Impact factor: 3.138